NGNENasdaqPharmaceutical PreparationsFiscal year ends December 31
Neurogene Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$24.17+0.92 (+3.96%)
Close on Oct 19, 2026
- Market cap
- $545.08M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Operating margin
–
Net margin
–
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -29.2% | -20.0% | -31.4% | |
| Return on assets | -27.6% | -18.6% | -28.9% | |
| Current ratio | 10.87 | 24.66 | 16.56 | |
| Interest coverage | -37645.0× | – | -20665.6× | |
| Capex to revenue | – | – | – | |
| Diluted shares | 4M | 10M | 21M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Neurogene generated $299.58M from operations and spent $7.81M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$299.58M
Used
$7.81M
Capital expenditure$7.81M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-8123.7%
×Asset turnover0.00×
×Equity multiplier1.12×
=Return on equity, FY2024-30.3%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2024 | -8123.7% | 0.00× | 1.12× | -30.3% |
| FY2018 | -126.3% | 0.27× | 1.10× | -36.8% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$90.35M
- Cash generatingOperating cash flow above zero-$77.17M
- Return on assets improvedROA up on the prior year-33.8% → -26.9%
- Earnings backed by cashOperating cash flow above net income-$77.17M vs -$90.35M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose20.84 → 16.56
- No dilutionShare count did not rise18M → 21M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.00 → 0.00